Professor, Medicine
School of Medicine

Cirrhosis, Viral hepatitis, Alcoholic Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease

Dr. Morgan’s clinical research interest is treatment metabolic dysfunction-associated steatotic liver disease (MASLD). He has alco conducted clinical trial in alcoholic liver disease and hepatitis C.

2022 Researcher of the Year, VA Long Beach Healthcare System
2021 Researcher of the Year, VA Long Beach Healthcare System
2013 Long Beach VA Inpatient Attending Teaching Award
2013 National Cancer Institute Clinician Award
2012 Special Award from the University of California for being an Outstanding Clinical
Researcher (leading enroller) for Clinical Trials funded by the Division of Cancer
Prevention, National Cancer Institute
2006 Outstanding Teacher, UCI and VA Gastroenterology Fellows
2006 Certificate of Appreciation, VA National Liver Transplant Program,
VA Central Office, Washington, DC
2001 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1994 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1974 Phi Beta Kappa, Northwestern University

1. Lim AS, Cruz SN, Asghar A, Malysheva O, Caudill MA, Alonso C, Montilla A, Karsdal MA, Leeming DJ, Mayorca-Guiliani AE, Svejso FH, McClain CJ, Morgan TR. Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase. Hepatology 2025 (in press)
2. Dounel J, Lamorte C, Patton H, Perumalswami P, McCurdy H, Kim NJ, Beste LA, Scott D, Casey J, Spoutz P, Chia L, Yao Y, Lowy E, Gibson S, Morgan TR, Rogal SS. Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach. BMC Health Serv Res. 2025 Jan 29;25(1):168. [PMID: 39875981]
3. Niezen S, Morgan TR, Scott D, Yakovchenko V, Patton H, Spoutz P, Yao Y, Baffy G, Fuchs M, Bajaj JS, Ekanem NR, Dominitz JA, Rogal SS. Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans. Am J Gastroenterol. 2025 Jan 7. [PMID: 39774063]
4. Morgan TR. Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape. Clin Liver Dis. 2024 Nov;28(4):747-760. [PMID: 39362719]
5. Arab JP, Díaz LA, Rehm J, Im G, Arrese M, Kamath PS, Lucey MR, Mellinger J, Thiele M, Thursz M, Bataller R, Burton R, Chokshi S, Francque SM, Krag A, Lackner C, Lee BP, Liangpunsakul S, McClain C, Mandrekar P, Mitchell MC, Morgan MY, Morgan TR, Pose E, Shah VH, Shawcross D, Sheron N, Singal AK, Stefanescu H, Terrault N, Trépo E, Moreno C, Louvet A, Mathurin P. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol 2025;82(4):744-756. [PMID: 39608457]
6. Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology 2025;81(1):312-320. [PMID: 39422487]
7. Morgan TR. Emerging pharmacologic treatments for alcohol-associated hepatitis: current status and future landscape. Clin Liver Dis 2024;28(4):747-760 [PMID: 39362710]
8. Tapper EB, Warner MA, Shah RP, Emamaullee J, Dunbar NM, Sholzberg M, Poston JN, Soto RJ, Sarwar A, Pillai A, Reyner K, Mehta S, Ghabril M, Morgan TR, Caldwell S. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024 Aug 1;80(2):488-499. [PMID: 38557474]
9. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; Healthy Livers, Healthy Lives Collaborators. [TR Morgan, member]. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol 2023;79(3):618-634. [PMID: 37353401].
10. Mary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, Sven M Francque, Arun J Sanyal, Fasiha Kanwal, Diana Romero, Manal F Abdelmalek, Quentin M Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D Byrne, Graciela E Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D Guy, Stephen A Harrison, Seung Up Kim, Bart G Koot, Marko Korenjak, Kris V Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R Morgan, Elisabeth E Powell, Michael Roden, Manuel Romero-Gómez, Marcelo Silva, Shivaram Prasad Singh, Silvia C Sookoian, C Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N Newsome; NAFLD Nomenclature consensus group. A multi-society Delphi Consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79(6):1542-1556 [PMID 37364790]

2022 – 2032 Preventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM Study). VA Cooperative Studies Program (CSP) #2023 Co-PI at VA Long Beach ~$150,000/year (estimated) 2012 – 2029 Network of Dedicated Enrollment Sites (NODES) VA Cooperative Studies Program Site Investigator at VA Long Beach Healthcare System ~$500,000/year (estimated) 2011 – 2026 Million Veteran Program VA Cooperative Studies Program (G002) Principal Investigator at VA Long Beach Healthcare System ~$175,000/year (estimated)

American Association for the Study of Liver Diseases

American Gastroenterological Association

Link to this profile
https://faculty.uci.edu/profile/?facultyId=3093

Last updated
08/11/2025